SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1999 |
| PE ASSETS | 1.9B EUR |
| Size | Large |
| Type | Sector Agnostic |
Bencis is an independent private equity firm focused on investments in profitable, established companies headquartered throughout Western Europe. Target businesses typically generate sales of €25 to €500 million and operate in the industrial/manufacturing, food/beverages, logistics/distribution, chemicals, automotive, leisure, media, services, utilities and retail industries. Bencis was formed in 1999 and is based in Amsterdam, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 36 of 77 |
| Sector: Machinery M&A | 1 of 2 |
| Type: Going Private M&A Deals | 2 of 2 |
| Country: Netherlands M&A | 29 of 55 |
| Year: 2013 M&A | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-04-09 |
Florimex International B.V.
Aalsmeer, Netherlands Florimex International B.V. is a distributor of horticultural products. With more than 30 branches and numerous representatives, Florimex International is at home all over the world. Worldwide, Florimex holds the number one position in the market. Thousands of employees around the globe take care of daily imports and exports of a wide range of flowers, plants and foliage. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-02 |
Voogd & Voogd
Middelharnis, Netherlands Voogd & Voogd is a technology-enabled insurance distribution and software platform. Providing a range of value-added administrative services and solutions, the company’s platform forms the commercial and logistical link between insurers and c.2,000 brokers in Netherlands. Voogd & Voogd was founded in 1909 and is based in Middelharnis, Netherlands. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 2.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.
| DEAL STATS | # |
|---|---|
| Overall | 82 of 170 |
| Sector: Machinery M&A | 4 of 7 |
| Type: Going Private M&A Deals | 1 of 1 |
| Country: Netherlands M&A | 24 of 42 |
| Year: 2013 M&A | 8 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-06-28 |
Prosensa
Leiden, Netherlands Prosensa is an operator of a biotechnology company that uses a unique and revolutionary licensed technology platform that makes use of so-called exon skipping for correcting mutated RNA. Prosensa company primarily targets Duchenne Muscular Dystrophy (DMD) disorder, against which it has already developed two products that are currently in clinical phase I / II. Prosensa was founded in 2002 and is based in Leiden, Netherlands. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-19 |
Endosense SA
Meyrin, Switzerland Endosense was founded in 2003 in Geneva. It develops and commercialises TactiCath®, a unique catheter used for treating cardiac rhythm disorders. Catheter ablation is a treatment whereby a special catheter is advanced into the patient's left heart chamber via the femoral vein. TactiCath® improves the safety and effectiveness of catheter ablation treatment. The optic fibres of the catheter measure the contact force between the catheter and the beating heart wall. This to avoid that the contact force is too slight, reducing the effectiveness of the treatment, or that the contact force is too great, risking heart wall perforation. Since heart fluttering is meanly related to old age and the population is ageing, the demand for catheter ablation is expected to increase swiftly. |
Sell | $171M |
